11:10–11:35

Abstract 5500

A randomized phase 2 trial comparing   efficacy of the combination of the PARP inhibitor olaparib and the   antiangiogenic cediranib against olaparib alone in recurrent   platinum-sensitive ovarian cancer.

铂敏感复发卵巢癌中PARP抑制剂olaparib联合抗血管生成剂cediranib对比单药olaparib的II期随机研究。

李  宁(Ning   Li)

Abstract 5502

Molecular subgroup of high-grade serous   ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab.

预测卵巢高级别浆液性癌（HGSOC）贝乏珠单抗疗效的分子亚群。

Abstract   5504

Progression-free   survival in ovarian cancer patients in second remission with mucin-1   autologous dendritic cell therapy.

卵巢癌患者粘蛋白1自体树突状细胞治疗再次缓解后的无进展生存期。

11:35–11:45

专家评述

Discussion   Topic: Current status of molecular targeted therapy for ovarian cancer

讨论主题：卵巢癌分子靶向治疗的现状

阳志军(Zhi-Jun Yang)

11:45-11:50

讨论(Q &   A)

吴令英(Ling-Ying Wu)

吴小华(Xiao-Hua Wu)

阳志军(Zhi-Jun Yang)